CoChat
Sign Up
Cited by 245

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Kumar, Shaji K, Jacobus, Susanna J, Cohen, Adam D, Weiss, Matthias, Callander, Natalie, Singh, Avina K, Parker, Terri L, Menter, Alexander, Yang, Xuezhong, Parsons, Benjamin, Kumar, Pankaj, Kapoor, Prashant, Rosenberg, Aaron, Zonder, Jeffrey A, Faber, Edward, Lonial, Sagar, Anderson, Kenneth C, Richardson, Paul G, Orlowski, Robert Z, Wagner, Lynne I, Rajkumar, S Vincent·2020·The Lancet Oncology
DOI 10.1016/s1470-2045(20)30452-6PMC PMC7591827
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(20)30452-6

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 32

  1. Kumar, 2018, The multiple myelomas—current concepts in cytogenetic classification and therapy, Nat Rev Clin Oncol, 15, 409, 10.1038/s41571-018-0018-y · DOI · Paper page
  2. Dimopoulos, 2020, Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma, Blood Cancer J, 10, 17, 10.1038/s41408-020-0273-x · DOI
  3. Costa, 2017, Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States, Blood Adv, 1, 282, 10.1182/bloodadvances.2016002493 · DOI
  4. Kumar, 2014, Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients, Leukemia, 28, 1122, 10.1038/leu.2013.313 · DOI
  5. Munshi, 2017, Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis, JAMA Oncol, 3, 28, 10.1001/jamaoncol.2016.3160 · DOI
  6. Richardson, 2010, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma, Blood, 116, 679, 10.1182/blood-2010-02-268862 · DOI · Paper page
  7. Kumar, 2012, Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma, Blood, 119, 4375, 10.1182/blood-2011-11-395749 · DOI · Paper page
  8. Durie, 2017, Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial, Lancet, 389, 519, 10.1016/S0140-6736(16)31594-X · DOI · Paper page
  9. O'Donnell, 2018, A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma, Br J Haematol, 182, 222, 10.1111/bjh.15261 · DOI
  10. Joseph, 2020, Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma, J Clin Oncol, 38, 1928, 10.1200/JCO.19.02515 · DOI · Paper page
  11. Kuhn, 2007, Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma, Blood, 110, 3281, 10.1182/blood-2007-01-065888 · DOI
  12. Jakubowiak, 2012, A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma, Blood, 120, 1801, 10.1182/blood-2012-04-422683 · DOI
  13. Korde, 2015, Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma, JAMA Oncol, 1, 746, 10.1001/jamaoncol.2015.2010 · DOI
  14. Facon, 2019, Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma, Blood, 133, 1953, 10.1182/blood-2018-09-874396 · DOI
  15. Kumar, 2016, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, 17, e328, 10.1016/S1470-2045(16)30206-6 · DOI · Paper page
  16. Jacobus, 2016, Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen, Blood Cancer J, 6, e448, 10.1038/bcj.2016.55 · DOI
  17. Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 · DOI · Paper page
  18. Mantel, 1966, Evaluation of survival data and two new rank order statistics arising in its consideration, Cancer Chemother Rep, 50, 163
  19. Cox, 1972, Regression models and life-tables, J R Stat Soc B, 34, 187, 10.1111/j.2517-6161.1972.tb00899.x · DOI · Paper page
  20. O'Brien, 1979, A multiple testing procedure for clinical trials, Biometrics, 35, 549, 10.2307/2530245 · DOI · Paper page
  21. Wieand, 1994, Stopping when the experimental regimen does not appear to help, Stat Med, 13, 1453, 10.1002/sim.4780131321 · DOI
  22. Kazandjian, 2018, Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: five-year follow-up of a phase 2 clinical trial, JAMA Oncol, 4, 1781, 10.1001/jamaoncol.2018.5457 · DOI
  23. Gay, 2019, Efficacy of carfilzomib lenalidomide dexamethason (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: results from the FORTE trial, Proc Am Soc Clin Oncol, 37
  24. Dimopoulos, 2016, Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study, Lancet Oncol, 17, 27, 10.1016/S1470-2045(15)00464-7 · DOI
  25. Moreau, 2008, Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma, Haematologica, 93, 1908, 10.3324/haematol.13285 · DOI
  26. Danhof, 2016, ‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma—analysis of cardiac toxicity and predisposing factors, Eur J Haematol, 97, 25, 10.1111/ejh.12677 · DOI
  27. Mina, 2020, Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies, Haematologica
  28. D'Souza, 2020, Current use of and trends in hematopoietic cell transplantation in the United States, Biol Blood Marrow Transplant, 26, e177, 10.1016/j.bbmt.2020.04.013 · DOI
  29. Fermand, 1998, High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial, Blood, 92, 3131, 10.1182/blood.V92.9.3131 · DOI · Paper page
  30. Moreau, 2019, Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study, Lancet, 394, 29, 10.1016/S0140-6736(19)31240-1 · DOI
  31. Mateos, 2018, Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma, N Engl J Med, 378, 518, 10.1056/NEJMoa1714678 · DOI
  32. Kapoor, 2019, MAIA under the microscope—bringing trial design into focus, Nat Rev Clin Oncol, 16, 339, 10.1038/s41571-019-0198-0 · DOI

Cited by

Sorted by citations

See all 245

Metadata

Authors
Kumar, S. K., Jacobus, S. J., Cohen, A. D., Weiss, M., Callander, N., Singh, A. K., Parker, T. L., Menter, A., Yang, X., Parsons, B., Kumar, P., Kapoor, P., Rosenberg, A., Zonder, J. A., Faber, E., Lonial, S., Anderson, K. C., Richardson, P. G., Orlowski, R. Z., Wagner, L. I., & Rajkumar, S. V.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2020-10
Volume
21
Issue
10
Pages
1317-1330
ISSN
1470-2045
DOI
10.1016/s1470-2045(20)30452-6
PMC
PMC7591827
Cited by
245
References
3
Language
en
Licence
Funders
NCI (U10CA180820, U10CA180794, UG1CA189828, UG1CA232760, UG1CA189956, UG1CA233277, UG1CA189863, U10CA180888, UG1CA233337, UG1CA189821, U10CA180821, UG1CA189858, UG1CA189830, UG1CA233340, UG1CA233163, UG1CA189957, UG1CA233247, UG1CA233180, UG1CA233329)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review